Dr. Robert J. Szalewski, M.D.
Allergy & Immunology (Allergy & Immunology Physician)
600 N Cotner Blvd Ste 208
Lincoln, NE 68505
Who else practices at this address →
Lancaster County is a federal mental health shortage area. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Nebraska College of Medicine (2015)
- Years since graduation
- 11
- In the NPI registry since
- 2015
- Medicare patients seen, 2024
- 464
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2015Medical school: University of Nebraska College of Medicine
- 2015Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Allergy & Immunology Physician primary
NE license 32292
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Bryan Medical Center Lincoln, NE
- The Nebraska Methodist Hospital Omaha, NE
- Chi Health St. Elizabeth Lincoln, NE
- Memorial Hospital Aurora, NE
- Community Medical Center, Inc Falls City, NE
Medical groups
- Allergy Asthma and Immunology Associates PC (15 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 464
- Services billed
- 19,720
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Injection, mepolizumab, 1 mg | 4,500 | 22 |
| Injection, omalizumab, 5 mg | 4,335 | 39 |
| Test for allergy using allergenic extract | 2,012 | 39 |
| Professional service for preparation and provision of 1 or more antigens | 619 | 76 |
| Injection, benralizumab, 1 mg | 420 | 12 |
| Professional service for multiple injections of allergen | 309 | 91 |
| Injection of drug or substance under skin or into muscle | 212 | 74 |
| Professional service for single injection of allergen | 155 | 57 |
| Established patient office or other outpatient visit, 20-29 minutes | 130 | 100 |
| Established patient office or other outpatient visit, 30-39 minutes | 117 | 77 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Montelukast Sodium Other prescribers in Lincoln, NE | 151 |
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Lincoln, NE | 138 |
| Azelastine Hcl Other prescribers in Lincoln, NE | 109 |
| Azithromycin Other prescribers in Lincoln, NE | 86 |
| Dupixent Pen (dupilumab) Other prescribers in Lincoln, NE | 56 |
| Ipratropium Bromide Other prescribers in Lincoln, NE | 52 |
| Hizentra (immun glob g(igg)/pro/iga 0-50) | 47 |
| Xembify (immune globulin,gamma(igg)klhw) | 45 |
| Fluticasone Propionate Other prescribers in Lincoln, NE | 43 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Lincoln, NE | 40 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 24 companies reported 149 payments worth $26,693 in total to this clinician.
| AstraZeneca Pharmaceuticals LP | $12,031 |
|---|---|
| Genzyme Corporation | $6,699 |
| Pharming Healthcare, Inc. | $3,883 |
| Consortium of Independent Immunology Clinics, LLC | $1,226 |
| Takeda Pharmaceuticals U.S.A., Inc. | $835 |
| Novartis Pharmaceuticals Corporation | $361 |
| Adma Biomanufacturing LLC | $294 |
| Csl Behring | $251 |
| Consulting Fee | $11,360 |
|---|---|
| Compensation for services other than consulting (speaking, faculty) | $11,300 |
| Food and Beverage | $3,645 |
| Travel and Lodging | $315 |
| Education | $72.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Jun 11, 2025 | Consulting Fee | $5,302 |
| AstraZeneca Pharmaceuticals LP Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,250 |
| AstraZeneca Pharmaceuticals LP May 15, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,250 |
| Pharming Healthcare, Inc. Jun 19, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $2,500 |
| AstraZeneca Pharmaceuticals LP Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Mar 3, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| Pharming Healthcare, Inc. Jun 12, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $1,250 |
| Consortium of Independent Immunology Clinics, LLC Apr 16, 2025 | Consulting FeeCompany’s descriptionconsulting | $1,226 |
| Takeda Pharmaceuticals U.S.A., Inc. May 12, 2025 | Consulting Fee | $788 |
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $450 |
All 17 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $450 |
| Adma Biomanufacturing LLC Nov 7, 2025 | Consulting Fee | $122 |
| AstraZeneca Pharmaceuticals LP Nov 3, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| Adma Biomanufacturing LLC Oct 7, 2025 | Consulting Fee | $173 |
| AstraZeneca Pharmaceuticals LP Jul 8, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $100 |
| AstraZeneca Pharmaceuticals LP Jul 3, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $250 |
| Pharming Healthcare, Inc. Jun 19, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $2,500 |
| Pharming Healthcare, Inc. Jun 12, 2025 | Consulting Fee RUCONEST · BIOLOGIC | $1,250 |
| Genzyme Corporation Jun 11, 2025 | Consulting Fee | $5,302 |
| Genzyme Corporation Jun 11, 2025 | Travel and Lodging travel to Dallas, TX, TX · in-kind | $315 |
| AstraZeneca Pharmaceuticals LP May 15, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,250 |
| Takeda Pharmaceuticals U.S.A., Inc. May 12, 2025 | Consulting Fee | $788 |
| Consortium of Independent Immunology Clinics, LLC Apr 16, 2025 | Consulting FeeCompany’s descriptionconsulting | $1,226 |
| Sanofi-aventis U.S. LLC Mar 28, 2025 | Education DUPIXENT · Immunology · in-kind | $72.00 |
| AstraZeneca Pharmaceuticals LP Mar 3, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $1,850 |
| AstraZeneca Pharmaceuticals LP Jan 20, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $300 |
| AstraZeneca Pharmaceuticals LP Jan 17, 2025 | Compensation for services other than consulting (speaking, faculty) TEZSPIRE · Respiratory Company’s descriptionSpeaker Fee | $3,250 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 14 industry-funded studies in 2025, from 8 companies. The companies reported $410,844 in research payments for these studies, mostly to the institutions running them.
- A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Efficacy and Safety Study of Tezepelumab in Patients with Eosinophilic Esophagitis (CROSSING)
AstraZeneca Pharmaceuticals LP - A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Amgen Inc. - A randomized,double blind,multicenter,parallel group,phase IIIb 52 week study evaluating the efficacy and safety of PT027 compared with PT007 administered as needed in participants 12 to under 18 years of age with as…
AstraZeneca UK Limited - A Phase 3, Multicenter, Double-blind Maintenance Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Subjects With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-ASC…
Amgen Inc. - A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal and Open-label Extension Study Followed by Long-term Open-label Treatment Cycles to Assess the Efficacy, Safety and Tolerability of Remibrutinib (…
Novartis Pharmaceuticals Corporation - A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler
AstraZeneca Pharmaceuticals LP - A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis
AbbVie Inc. · Active, not recruiting · NCT06718101 - A Phase 3, Randomized, 24-week, Placebo-controlled, Double-blind Study to Assess the Efficacy, Safety and Tolerability of Rocatinlimab (AMG 451) Monotherapy in Adult Subjects With Moderate-to-severe Atopic Dermatitis …
Amgen Inc. - A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis
Sanofi US Services Inc. · Completed · NCT06130566 - Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE)
Regeneron Pharmaceuticals, Inc. · Completed · NCT04394351
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.